anti-cd47 neutralizing antibody acd47 (Bio X Cell)
Structured Review

Anti Cd47 Neutralizing Antibody Acd47, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd47 neutralizing antibody acd47/product/Bio X Cell
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "CD47 antibody protects mice from doxorubicin-induced myocardial damage by suppressing cardiomyocyte apoptosis"
Article Title: CD47 antibody protects mice from doxorubicin-induced myocardial damage by suppressing cardiomyocyte apoptosis
Journal: Experimental and Therapeutic Medicine
doi: 10.3892/etm.2022.11277
Figure Legend Snippet: aCD47 significantly reduces the severity of Dox-induced dilated cardiomyopathy (DCM) in mice. Adult mice (aCD47/Dox group) were i.p. administered with both 7 mg/kg aCD47 and 10 mg/kg Dox once a week for 4 weeks. Mice treated with both IgG isotype and Dox (IgG/Dox group) or PBS and aCD47 alone (PBS and aCD47 groups) were controls. (A) Hematoxylin and eosin (H&E) staining for mouse heart tissues. Representative gross morphology and phase contrast microscope images with x200 magnification (upper two panels). Masson staining for interstitial fibrosis and immunostaining for collagen I (lower two panels). Representative images with x200 magnification. Red arrow, cells with centrally localized nuclei; blue arrow, broken and patchy myofibers; yellow arrow, interstitial fibrosis; green, collagen I. (B) Representative echocardiograms of mice 4 weeks after treatment. (C) Quantitative analysis of echocardiographic measurements. Left ventricular ejection fraction (LVEF); left ventricular fractional shortening (LVFS). (D) Quantitative analysis of cardiomyocyte area after H&E staining (upper panel; Mann-Whitney test) and fluorescence intensity of collagen I-positive fibers in heart tissues after immunostaining by ImageJ software. Data are presented as relative fluorescence intensity of positively stained cells over untreated controls. (E) Western blot analysis for the expression of collagen I, Bax and Bcl-2 in the cardiac tissues of treated mice. GAPDH was internal loading control. One representative blot. (F) Band densitometric intensity was semi-quantified by ImageJ software. (G) Flow cytometry analysis for the infiltrating CD11b + macrophages in cardiac tissues. (H) The infiltrating CD11b + macrophages in cardiac tissues were measured by flow cytometry and quantitatively analyzed. All quantitative data are presented as mean ± standard error. * P<0.05, ** P<0.01 vs. PBS group; # P<0.05, ## P<0.01 vs. IgG/Dox group (n=5-7). Two-way ANOVA with Tukey's multiple comparison's test, except where it is indicated otherwise. aCD47, anti-CD47 neutralizing antibody; Dox, doxorubicin.
Techniques Used: Staining, Microscopy, Immunostaining, MANN-WHITNEY, Fluorescence, Software, Western Blot, Expressing, Control, Flow Cytometry, Comparison
Figure Legend Snippet: aCD47 suppresses the expression of cardiac myofiber early apoptosis and production of pro-inflammatory cytokines in mice with Dox-induced DCM. (A) Cardiac myofiber apoptosis in the treated mice was analyzed by flow cytometry analysis. Annexin V + 7-AAD - cells were identified as early apoptotic cells. Annexin V + 7-AAD + cells were identified as late apoptotic cells. Representative dot plot. (B) Quantitative analysis of apoptotic cells after flow cytometry analysis. ** P<0.01 vs. untreated mice; ## P<0.05 vs. mice treated with Dox alone, n=5-7. Two-way ANOVA with Tukey's multiple comparison's test. (C) Different doses of aCD47 (3.5, 7 and 14 mg/kg) on apoptosis of cardiac myofiber in mice with DCM. Representative dot plot (left panel). Quantitative analysis of early apoptotic cells (right panel). * P<0.05 and ** P<0.01 vs. untreated mice; # P<0.05 vs. mice treated with Dox alone (Dox/0 group), n=3/group. Two-way ANOVA with Tukey's multiple comparison's test. (D) Measurement of LDH release in serum. Data are presented as mean ± standard error (Mann-Whitney test). (E) Quantitative analysis of Bax and Bcl-2 expression in cardiac tissues of treated mice in . Data are presented as the ratio of band densitometric intensity over untreated control. (F) Ratio of Bcl-2/Bax expression in lung tissues of treated mice analyzed by western blot analysis in . (G) Immunostaining for Bax (red) in the cardiac tissues of treated mice. Representative images with x200 magnification. (H) Quantitative analysis for Bax expression in the stained cells by ImageJ software. Data are presented as the fluorescence intensity over controls. (I and J) ELISA analysis for the expression of TNF-a in serum and IL-6 in heart protein extracts. Data are presented as mean ± standard error. ** P<0.01 vs. PBS group; # P<0.05, ## P<0.01 vs. IgG/Dox group (n=5-7). Two-way ANOVA with Tukey's multiple comparison's test, except where it is indicated otherwise. aCD47, anti-CD47 neutralizing antibody; Dox, doxorubicin; LDH, lactate dehydrogenase.
Techniques Used: Expressing, Flow Cytometry, Comparison, MANN-WHITNEY, Control, Western Blot, Immunostaining, Staining, Software, Fluorescence, Enzyme-linked Immunosorbent Assay
Figure Legend Snippet: aCD47 reduces Dox-induced cardiomyocyte early apoptosis. The cultured primary cardiomyocytes were pre-treated with 1 µg/ml aCD47 for 1 h, which was followed by treatment with 10 µM Dox (aCD47/Dox group) for 24 h. The cells treated with both Dox and isotype IgG (IgG/Dox), untreated or treated with aCD47 alone (aCD47 group) were controls. (A) Flow cytometry analysis for Annexin V + 7-AAD - apoptotic cardiomyocytes 24 h after treatment. Representative dot plots. (B) Quantitative analysis for apoptotic cardiomyocytes analyzed by flow cytometry. (C) Cell viability was determined by CCK-8 assay. Data are presented as the ratio of optical density at 450 nm (OD450 nm) over untreated control. (D) LDH release into the supernatant of the treated cells. Data are presented as the fold increase over untreated controls. Bar plot data in all panels represent the mean ± standard error. n=3. ** P<0.01 vs. 0 group; # P<0.05 vs. IgG/Dox group. Two-way ANOVA followed by a Tukey's multiple comparison's test. aCD47, anti-CD47 neutralizing antibody; Dox, doxorubicin; LDH, lactate dehydrogenase.
Techniques Used: Cell Culture, Flow Cytometry, CCK-8 Assay, Control, Comparison
Figure Legend Snippet: aCD47 reduces the expression of Bax and p-p38 MAPK in Dox-treated cardiomyocytes. (A) Immunostaining for the expression of cTnT, cleaved caspase-1/3, Bax and p-p38 MAPK in the treated cardiomyocytes. Cardiomyocytes were identified as cTnT-positive cells (green). Red, cells positively stained for cleaved caspase-1/3, Bax and p-p38 MAPK. Representative images with x200 magnification. (B) Semi-quantitative analysis of positively stained cells by ImageJ software. Data are presented as the relative intensity of positively stained cells over untreated controls. (C) Western blot analysis for the expression of pro-caspase-1, cleaved caspase-1, cleaved caspase-3, Bax and Bcl-2 in the treated cardiomyocytes. GAPDH was internal loading control. One representative blot. (D) p-p38 MAPK + cells after Dox and aCD47 treatment were analyzed by flow cytometry. Data are presented as the percentage of p-p38 MAPK + cells. (E) Association between the percentage of p-p38 MAPK + cells and apoptotic cardiomyocytes after treatment. Bar plot data in all panels are represented as mean ± standard error. n=3. * P<0.05, ** P<0.01 vs. 0 group; # P<0.05, ## P<0.01 vs. IgG/Dox group. Two-way ANOVA followed by a Tukey's multiple comparison's test. aCD47, anti-CD47 neutralizing antibody; Dox, doxorubicin; p-, phosphorylated; cTnT, cardiac troponin T.
Techniques Used: Expressing, Immunostaining, Staining, Software, Western Blot, Control, Flow Cytometry, Comparison